A股異動 | 承德露露漲近6% 擬以2億元-4億元回購股份
格隆匯4月12日丨承德露露(000848.SZ)漲5.98%,報8.68元,總市值93億元。承德露露11日公吿,公司擬使用自有資金2億元-4億元以集中競價交易的方式回購股份,用於註銷減少註冊資本。回購價格不超過13.30元/股。另外,公司同日發佈2021 年年度報吿,該公司營業收入25.24億元,同比增長35.65%。歸屬於上市公司股東的淨利潤5.7億元,同比增長31.77%。歸屬於上市公司股東的扣除非經常性損益的淨利潤5.68億元,同比增長32.17%。基本每股收益0.54元。本年營業收入較上年收入增長的主要原因是市場內需逐步恢復,同時加強空白市場開發,導致產品銷量增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.